Results 181 to 190 of about 77,580 (287)

Anti- and non-tumor necrosis factor-α-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. [PDF]

World J Diabetes, 2021
Wang CR, Tsai HW.
europepmc   +1 more source

Patch Testing Under Biologics: Six Cases From a Tertiary Centre

Contact Dermatitis, EarlyView.
Alessandra Chiei‐Gallo, Francesca Barei, Angelo V. Marzano, Silvia M. Ferrucci   +3 more
wiley   +1 more source

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami, Yukari Okubo, Satomi Kobayashi, Natsuko Kikuta, Yoshiumi Ouchi, Kenta Shishido, Tadashi Terui   +6 more
wiley   +1 more source

Safety of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting. [PDF]

Rheumatol Ther
Arendse R, Rahman P, Baer P, Haaland D, Bessette L, Sholter D, Rachich M, Rampakakis E, Marrache AM, Lehman AJ, Asin-Milan O.   +10 more
europepmc   +1 more source

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Bruce Strober, Melinda Gooderham, Wendy Zhang, Junichiro Shimauchi, Masafumi Yaguchi, Takeshi Kimura, Ryuichi Ogawa, Hamid Amouzadeh, Masamoto Murakami   +15 more
wiley   +1 more source

Serum extracellular matrix biomarkers in rheumatoid arthritis, psoriatic arthritis and psoriasis and their association with hand function. [PDF]

Sci Rep
Port H, Coppers B, Tragl S, Manger E, Niemiec LM, Bayat S, Simon D, Fagni F, Corte G, Bay-Jensen AC, Tascilar K, Hueber AJ, Schmidt KG, Schönau V, Sticherling M, Heinrich S, Leyendecker S, Bohr D, Schett G, Kleyer A, Holm Nielsen S, Liphardt AM.   +21 more
europepmc   +1 more source

Quantification of hand muscle volume and composition in patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. [PDF]

BMC Musculoskelet Disord, 2020
Friedberger A, Figueiredo C, Grimm A, d'Oliveira I, Bäuerle T, Rech J, Kleyer A, Simon D, Uder M, Schett G, Engelke K.   +10 more
europepmc   +1 more source

Impact of Variation in APOE on Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Sequencing and Genotyping in General Population Cohorts. [PDF]

ACR Open Rheumatol
Objective Emerging evidence suggests that apolipoprotein E (apoE) may be involved in the immune system and diseases driven by chronic inflammation. The impact of the full range of structural genetic variation in APOE for risk of rheumatoid arthritis, psoriasis, and psoriatic arthritis in the general population is not known.
Rasmussen KL, Luo J, Nielsen SF, Nordestgaard BG, Tybjærg-Hansen A, Frikke-Schmidt R.   +5 more
europepmc   +2 more sources

Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis [PDF]

, 2005
Baeten, Dominique, BOOTS, AM, CANETE, JD, De Keyser, Filip, De Rycke, Leen, FOELL, D, Kruithof, Elli, ROTH, J, VANDOOREN, BERNARD, Veys, Eric   +9 more
core  

Impact of weight‐loss interventions on psoriasis severity: A systematic review and meta‐analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Weight‐loss interventions were associated with clinically and statistically significant improvements in psoriasis severity (PASI and PASI 75) and quality of life (DLQI). These findings support the role of weight‐loss interventions as effective adjuncts to medical therapy and their integration into holistic psoriasis care.
Sarah Morrow, Poppy Hawkins, Christopher E. M. Griffiths, Thanasis G. Tektonidis, Eli Harriss, Jadine Scragg, Susan Jebb   +6 more
wiley   +1 more source